TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes

TheracosBio announced that Brenzavvy™, an FDA-approved oral sodium-glucose cotransporter 2 inhibitor, is now available by prescription through the Mark Cuban Cost Plus Drug Company, PBC.

Scroll to Top